Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
6/18/25 | Scholar Rock (SRRK) | Apitegromab for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
6/17/25 | Mineralys (MLYS) | Lorundrostat for Chronic Kidney Disease (CKD) | Subscribers Only | Subscribers Only | Subscribers Only |
6/17/25 | Mineralys (MLYS) | Lorundrostat for Hypertension (Systemic) | Subscribers Only | Subscribers Only | Subscribers Only |
6/16/25 | D&D Pharmatech | DD-01 for Non-Alcoholic Steatohepatitis (NASH) | Subscribers Only | Subscribers Only | Subscribers Only |
6/14/25 | Tonix Pharmaceuticals Holding (TNXP) | TNX-102 SL for Fibromyalgia | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/20/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/22/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/02/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |